Please login to the form below

Not currently logged in
Email:
Password:

Levest COC promises NHS cost savings

Combined oral contraception, Levest, has won an NHS contract as the preferred drug of its type for hospitals in England

In addition to being listed by the majority of retail pharmacy wholesalers and multiples, Morningside Healthcare's combined oral contraception (COC), Levest, has won an NHS contract as the preferred drug of its type for hospitals in England.

Levest contains levenogesterel 150μg and ethinylestradiol 30μg and costs £2.55 per 63 tablets, or the equivalent of just £0.85 per cycle. This makes it 10 per cent cheaper than competitor, Microgynon 30 (ethinylestradiol and levonorgestrel), which costs £2.82 per 63 tablet, or £0.94 per cycle.

With an estimated one million women in England currently prescribed Microgynon, the potential cost savings for the NHS in England are in excess of £1m a year.

Dr Al-Azzawi, consultant gynaecologist, comments: "The clinical data demonstrates that Levest is bioequivalent to Microgynon 30 and can be prescribed in place of it without any loss of contraceptive efficacy."

5th May 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics